PBH

Based on Prestige Consumer Healthcare Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Prestige Consumer Healthcare do?

Prestige Consumer Healthcare develops, markets, and sells over-the-counter health and personal care products. Its portfolio includes well-known brands across categories like pain relief, eye care, women's health, and digestive wellness. Products are sold through mass retailers, drug stores, and e-commerce channels in North America and internationally.

Does PBH pay dividends?

PBH does not currently pay a dividend. The company appears to prioritize capital allocation toward debt management and potential acquisitions rather than shareholder distributions. Investors seeking regular income should note this when evaluating PBH against dividend-paying healthcare peers.

When does PBH report earnings?

Prestige Consumer Healthcare reports on a quarterly cadence, consistent with most US-listed companies. For exact upcoming report dates, check the investor relations section of the company's official website, as our data source does not cover specific future earnings dates.

Is PBH a good stock to buy?

UQS Score rates PBH as Below Average overall. The Attractive Valuation and Good Quality pillar offer some positives, but Weak Moat and Weak Growth ratings raise questions about long-term competitive positioning. The complete pillar breakdown is available to UQS Pro members.

Is PBH overvalued?

UQS Score's Valuation pillar rates PBH as Attractive, suggesting the stock may be trading at a relative discount to its fundamental profile. However, valuation alone does not determine quality — the Weak Growth and Moat pillars are important context for interpreting that discount.

How does PBH compare to its competitors?

PBH's consumer OTC brand model differs from peers like Henry Schein, which serves professional healthcare practitioners, and Guardian Pharmacy Services, which focuses on institutional pharmacy. PBH's strength lies in its branded consumer portfolio, though its Weak Moat rating suggests limited pricing power relative to category leaders.

What is PBH's market cap bracket?

PBH is classified as a mid-cap stock. This places it in a segment of the market that can offer growth potential beyond large-cap stability but with more resources and track record than small-cap peers. Mid-cap healthcare companies often attract investors seeking a balance of growth and relative stability.

Who founded Prestige Consumer Healthcare?

Prestige Consumer Healthcare was founded in 1996 and is headquartered in Tarrytown, New York. The company was formerly known as Prestige Brands Holdings, Inc. before changing its name in 2018. Detailed founding history is publicly available through the company's official disclosures.

Is PBH a long-term quality investment?

As a long-term quality indicator, UQS Score rates PBH as Below Average. The Good Quality pillar reflects reasonable cash generation, but the Weak Moat and Weak Growth pillars suggest the business may face challenges sustaining competitive advantages and expanding earnings over time. Pro members can view the full multi-pillar analysis.

What is the main competitive advantage of Prestige Consumer Healthcare?

Prestige Consumer Healthcare's primary advantage lies in its portfolio of established OTC brand names with consumer recognition across multiple health categories. However, UQS Score's Weak Moat rating indicates this brand strength may not translate into durable pricing power or meaningful barriers against private-label or category competitors.

Prestige Consumer Healthcare Inc. shows solid profitability with healthy returns on capital and reasonable margins.

Prestige Consumer Healthcare Inc. faces growth headwinds with declining or stagnant revenue trends.

Prestige Consumer Healthcare Inc. has some risk factors including moderate leverage or solvency concerns.

Prestige Consumer Healthcare Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.

Prestige Consumer Healthcare Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for PBH.

The UQS (Unified Quality Score) for Prestige Consumer Healthcare Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Prestige Consumer Healthcare Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Prestige Consumer Healthcare Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.